Business
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"Teva Pharmaceutical Industries Ltd","displaySize":"","headline":null,"caption":"Teva Pharmaceutical Industries Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vrlzyJKRPwSh_YtGafCgLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Duvakitug was well tolerated and safety was consistent with the induction study","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Findings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":350,"olType":false},{"type":"text","content":"Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.","length":123,"tagName":"p"},{"type":"text","content":"PARSIPPANY, N.J. and PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi announced positive results from the RELIEVE UCCD long-term extension (LTE) study of duvakitug, an investigational human monoclonal antibody targeting TL1A, which showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis (UC) and Crohn’s disease (CD) that initially responded to the induction phase. RELIEVE UCCD LTE is a double-blind randomized study evaluating the long-term efficacy, safety, and tolerability of duvakitug in UC and CD, the two most common forms of inflammatory bowel disease (IBD).","length":725,"tagName":"p"},{"type":"text","content":"These longer duration data reinforce the efficacy from the RELIEVE UCCD phase 2b induction study, which demonstrated that patients achieved clinically meaningful response with duvakitug compared to placebo at week 14...